Sponsored Content for Roby Zomer

ASX listed medical marijuana player MGC Pharmaceuticals has received ethics approval to carry out phase two clinical trials into the benefits of its “CogniCann” product for dementia and Alzheimer's patients in early 2019. CogniCann is a GMP certified, pharmaceutical grade, medicinal cannabis product specifically developed for the treatment of dementia symptoms to improve specific cognitive functions.

MGC Pharmaceuticals expects revenues to rise thanks to strong demand for its range of 18 cannabis based skin care products that has prompted UK luxury retailer Harvey Nichols to make them available in two additional stores. The company said the exposure provided by its skin care products may also provide a ready made pathway to market for its fledgling medicinal cannabis business.

MGC Pharmaceuticals' manufacturing facility in Slovenia will now commence production of pharmaceutical grade cannabis derived medicines after receiving a manufacturing licence. The Brett Mitchell chaired company will now begin full scale manufacturing of its epilepsy drug CannEpil for final, independent validation before exportation into Australasia and Europe. CannEpil is already approved for use in Australia.

ASX-listed MGC Pharmaceuticals' bold foray into the global cosmetics market has hit another notable milestone, with luxury UK retailer Harvey Nichols announcing it will stock the company's MGC Derma and Derma Plus skin care lines. MGC says the iconic British retailer will carry the Perth-listed company's premium range of 18 products containing cannabidiol, the non-psychoactive ingredient in cannabis.

Sky & Space Global has hit a key milestone in its journey into the lucrative South American telco market, with the ASX-listed company successfully testing of its nano-satellite based communications network with major regional telco company Globalsat Group. Sky and Space Global says it is finalising a deal with Globalsat that will potentially see bandwidth from the network used across South America.

ASX-listed MGC Pharmaceuticals' proposed medical marijuana facility in Malta looks set to go ahead after landmark laws legalising medicinal cannabis were passed by the Southern European nation's Parliament. MGC is now on the verge of official approval for its 4,000 square metre facility that it aims to use to launch into the rapidly expanding EU medical marijuana market.

MGC Pharma has stepped up its offering in the multi-million-dollar cannabis-based skincare market, launching its second marijuana-infused dermatological product “CBD Herbal Replenish Cream” aimed at treating inflammatory skin conditions. The release of the company's skin repair product comes after successful clinical tests in Europe. It is the second of three products in MGC's cannabis skincare range.

MGC Pharmaceuticals has raised $5 million in an oversubscribed share placement to construct a 4,000 square metre state-of-the-art medical cannabis production and cultivation facility in Malta. MGC will build the fully-licensed medical cannabis facility after the company was awarded the landmark contract paving the way for it to operate a fully vertically-integrated medical marijuana operation in Europe.

MGC Pharma has produced its first batch of CannEpil, from its European cannabis factory and the company is now one step away from final certification that will green light the facility for full scale production of medical marijuana products. The drug is set to provide medical relief for epilepsy sufferers with initial sales revenue predictions of AU$1 million per annum for the first year of distribution.

MGC Pharma's new cannabis based diet and vegan vitamin supplement comes in seven different flavours to be sold in both capsule and powder form. The ASX-listed medical marijuana company is tapping into a growing global health supplement market estimated at over US$550 billion. The company said the product meets strict European Union guidelines and will be used to instil “inner health and wellbeing”.

ASX-listed medical cannabis player MGC Pharmaceuticals is set to achieve a major commercial milestone as it edges closer to getting the final green light for its European medical marijuana facility. The company expects to receive official approval for the Slovenian facility this month after being granted an interim licence in January, bringing an 18-month approvals process near to completion.

ASX-listed MGC Pharmaceuticals has been given the green light by Slovenian authorities, who have given the medical marijuana company's European medicinal cannabis production facility a tick of approval. The company has now cleared an important regulatory hurdle for the production of its products in Europe, whilst it also steps up the approvals process for the import of medicinal and beauty brands into Australia.

Revered UK online beauty store business Cult Beauty will distribute MGC Pharmaceuticals medical marijuana skin care products as part of an exclusive sales and marketing deal signed between the two companies. MGC said global distribution channels for its products had substantially expanded following an agreement that will bring many of its products to the fore on a global, web-based catwalk of quality cosmetic brands.

ASX-listed MGC Pharmaceuticals will fast track an Australian operational base to cultivate medicinal marijuana after the federal government announced a plan to legalise exports of cannabis-based medicines. MGC said the regulatory changes, expected to be in place from February, would allow it to establish a pharmaceutical grade medicinal cannabis cultivation strategy to target key export markets.

MGC Pharma is aiming to hit a series of new highs in 2018 with a number of medicinal and cosmetic cannabis products hitting the shelves in the new year as the company shifts into production phase. The Perth-listed company is moving into the final countdown on the launchpad to the release of its first medical marijuana product to designed treat severe cases of epilepsy.

ASX-listed MGC Pharma is set to rollout a marijuana-derived psoriasis treatment after clinical trials in Europe showed the product, CBD Herbal Repair Cream, was effective at relieving dermatological symptoms such as irritated and inflamed skin. The first product offering from MGC's Derma Plus line, is scheduled for launch in January and will be sold online and through existing channels.

ASX-listed Sky and Space Global has ramped up cyber-security safeguards on its nano-satellites by incorporating market-leading encryption hardware into the miniature orbital devices. Sky and Space says the integration of the encryption technology, carried out in collaboration with global cyber security provider Check Point, validates its ability to offer a premium service to high value tier-one customers.

MGC Pharmaceuticals have executed another major new medical marijuana deal, this time with a European medicinal cannabis product manufacturer and distributor that has signed on for annual sales worth at least $1m. New customer Mabsut Life says the deal is just the first in a series of agreements it expects with MGC Pharmaceuticals under a strategic partnership.

MGC Pharmaceuticals have signed a distribution deal with local pharmaceutical distributor HL Pharma to launch its cannabis-based epilepsy treatment, CannEpil, in Australia. MGC wants to target the more than 70,000 Australian sufferers of the condition and sees it as a significant additional revenue stream ahead. The company says it now has a pathway to deliver the drug to patients from 2018.

Whilst most other medical marijuana companies are still trying to work out how to make money, ASX-listed MGC Pharmaceuticals are busy collecting purchase orders for their cannabis based products. The company has signed a binding heads of agreement with local pharmaceutical distributor, HL Pharma to distribute MGC's low cost, cannabis based epilepsy drug CannEpil in Australia.

ASX-listed MGC Pharmaceuticals has signed the first of three sale agreements with Korean cosmetics manufacturer Varm Cosmo as part of the Perth-listed company's $40 million deal with the Asian skincare business. MGC says the initial $8 million order will be followed by two more orders in the coming weeks to complete the landmark cannabis supply agreement.

MGC Pharmaceuticals has hit a new high with expected monthly sales soaring to $3m from a $40m deal to supply its white labelled cannabis based cosmetic products to Korean cosmetics manufacturer, Varm Cosmo. The agreement is set to transform MGC Pharmaceuticals, Australia's leading listed medical cannabis company with its products supplied in bulk to Varm Cosmo.

ASX-listed MGC Pharmaceuticals have harvested over 4,000 kilograms of cannabis for use in their range of marijuana-derived products as the Perth-listed company progresses its promising growing operations in Europe. MGC's botanical division, largely based in the EU, is also on the verge of harvesting more than 450 medicinal cannabis plants for use in their genetic research program.

MGC Pharmaceuticals have strengthened their position as a market leader in the booming medical marijuana market, securing a distribution deal for their products in Central and Eastern Europe. The exclusive agreement was signed with leading pharmaceutical distribution company, Lenis and will see the Perth-listed company's cannabis-derived products made available in more than 15 countries in the region.